Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
24 Results for "
Cyclin E1
" in MedChemExpress (MCE) Product Catalog:
Products (24)
24 Results for "Cyclin E1" in MCE Product Catalog:
5
5 Cited Publications
Synonyms: PF-07104091 hydrate
PF-07104091 hydrate is a potent and selective CDK2/cyclin E1 and GSK3β inhibitor, with Kis of 1.16 and 537.81 nM, respectively. PF-07104091 hydrate has anti-tumor activity for cyclin E1-amplified cancers. (patent WO2020157652A2).
2
2 Cited Publications
Cat. No.: HY-N3389
CAS No.: 66056-19-7
Cat. No.: HY-172085
CAS No.: 3099543-90-2
Target:
Research Areas:
SH514 is an orally active IRF4 inhibitor (IC50 = 2.63 μM). SH514 binds to the IRF4-DBD domain, thereby inhibiting the interaction of IRF4 protein with DNA (KD = 1.28 μM). SH514 can inhibit the proliferation of IRF4-high-expressing NCI-H929 and MM.1R cells, and displays no cytotoxicity for normal cells. SH514 significantly downregulates the expression of IRF4 downstream target genes concentration-dependently. SH514 inhibits the expression of cell cycle-related proteins CDC2, Cyclin B1, Cyclin D1, Cyclin E1, and CMYC in Multiple Myeloma cells. SH514 can induce DNA damage and increase the expression of γH2AX. SH514 effectively inhibits the proliferation of multiple myeloma tumors .
Cat. No.: HY-164827
CAS No.: 2862772-71-0
Target:
Research Areas:
CDK2 degrader 3 is a selective CDK2 molecular glue-like degrader. CDK2 degrader 3 induces G1 cell cycle arrest in CCNE1-amplified cancer cells. CDK2 degrader 3 is applicable to breast cancer-related research .
Cat. No.: HY-170897
CAS No.: 3065079-44-6
CDK2-IN-40 is a CDK2 (Cyclin dependent kinase 2) inhibitor, extracted from patent WO 2024/254245 A1 (Example 1). CDK2-IN-40 inhibits CDK2/Cyclin E1 with an IC50 of ≤ 10 nM .
Cat. No.: HY-160643
CAS No.: 2927473-94-5
CDK2-IN-27 (compound 1) is a potent CDK2 inhibitor with IC50 values of <10, >10-20 nM for CDK2/cyclin E1, CDK2/cyclin B1, respectively .
Cat. No.: HY-185164
CAS No.: 3078069-29-8
Anticancer agent 302 (Example 1) is an anticancer agent. Anticancer agent 302 has a DC50 value of 199 nM for Cyclin E1 and an IC50 value of 133 nM for pRB. Anticancer agent 302 can be used for tumor research .
Cat. No.: HY-P74214
Purity: ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: CCNE1; Cyclin E Variant Ex7del; Prev. CCNE; Cyclin Et; G1/S-Specific Cyclin-E1; PCCNE1; Cyclin E Variant Ex5del; Cyclin E1; Cyclin Es
Species:
Source:
Cat. No.: HY-P72963
Purity: ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: CCNE1; Cyclin E Variant Ex7del; Prev. CCNE; Cyclin Et; G1/S-Specific Cyclin-E1; PCCNE1; Cyclin E Variant Ex5del; Cyclin E1; Cyclin Es
Species:
Source:
Cat. No.: HY-P72964
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CCNE1; Cyclin E Variant Ex7del; Prev. CCNE; Cyclin Et; G1/S-Specific Cyclin-E1; PCCNE1; Cyclin E Variant Ex5del; Cyclin E1; Cyclin Es
Species:
Source:
Cat. No.: HY-P701364
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CDK3; Cyclin-Dependent Kinase 3; Cyclin Dependent Kinase 3; Cyclin-Dependent Kinase; Cell Division Protein Kinase 3; CDKN3; CCNE1; Cyclin E Variant Ex7del; Prev. CCNE; Cyclin Et; G1/S-Specific Cyclin-E1; PCCNE1; Cyclin E Variant Ex5del; Cyclin E1; Cyclin
Species:
Source:
Cat. No.: HY-P701365
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CDK3; Cyclin-Dependent Kinase 3; Cyclin Dependent Kinase 3; Cyclin-Dependent Kinase; Cell Division Protein Kinase 3; CDKN3; CCNE1; Cyclin E Variant Ex7del; Prev. CCNE; Cyclin Et; G1/S-Specific Cyclin-E1; PCCNE1; Cyclin E Variant Ex5del; Cyclin E1; Cyclin
Species:
Source:
Cat. No.: HY-183273
CAS No.: 3087270-50-3
BRD4/AKT-IN-1 is a BRD4/AKT inhibitor with BRD4 IC50 66.12 nM and AKT1 IC50 143.81 nM. BRD4/AKT-IN-1 blocks BRD4-mediated c-Myc transcriptional regulation, modulates AKT1 signaling, decouples AKT phosphorylation from pro-survival effectors. BRD4/AKT-IN-1 induces G0/G1 cell cycle arrest via downregulated phosphorylated RB, cyclin E1, CDK2. BRD4/AKT-IN-1 elevates LC3B levels to promote autophagy. BRD4/AKT-IN-1 promotes apoptosis in cancer cells. BRD4/AKT-IN-1 can be used for the research of metastatic castration-resistant prostate cancer .
Cat. No.: HY-181727
Target:
Research Areas:
AR/AR-V7 degrader-1 is an orally active AR and AR-V7 degrader. AR/AR-V7 degrader-1 disrupts the interaction between AR/AR-V7 and HSP90, leading to their ubiquitination and degradation in castration-resistant prostate cancer cells. AR/AR-V7 degrader-1 regulates the expression of cell cycle-related proteins in prostate cancer cells (downregulates CDK4, CDK6, Cyclin D1, Cyclin E1; upregulates P21) and induces G0/G1 phase arrest. AR/AR-V7 degrader-1 inhibits the proliferation and migration of prostate cancer cells. AR/AR-V7 degrader-1 suppresses the growth of castration-resistant prostate cancer tumors in nude mice and induces the degradation of AR and AR-V7 in tumor tissues. AR/AR-V7 degrader-1 is applicable to the research of castration-resistant prostate cancer .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
